Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide.

被引：0
|
作者：
Badros, A
Zangari, M
Bodenner, D
Siegel, E
Spoon, D
Toor, A
Desikan, R
Arnold, E
Anaissie, E
Zeldis, J
Tricot, G
Barlogie, B
机构：
[1] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Endocrinol, Little Rock, AR 72205 USA
[3] Celgene Corp, Warren, NJ USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4973
引用
收藏
页码：285B / 285B
页数：1
相关论文
共 50 条
  • [21] Thalidomide in elderly patients with multiple myeloma
    Kusumi, Eiji
    Matsumura, Tomoko
    Yuji, Koichiro
    Tanaka, Yuji
    Kami, Masahiro
    LANCET, 2006, 367 (9527): : 1977 - 1977
  • [22] Durable response to thalidomide in relapsed/refractory multiple myeloma (MM).
    Raza, SN
    Veksler, Y
    Sabir, T
    Li, ZJ
    Anderson, L
    Jagannath, S
    BLOOD, 2000, 96 (11) : 168A - 169A
  • [23] Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM).
    Shima, Y
    Treon, SP
    Yoshizaki, K
    Tai, YT
    Hideshima, T
    Raje, N
    Chauhan, D
    Davies, F
    Schlossman, R
    Anderson, KC
    BLOOD, 1999, 94 (10) : 125A - 125A
  • [24] Impact on Response and Survival of DNA Repair Single Nucleotide Polymorphisms In Relapsed or Refractory Multiple Myeloma Patients Treated with Thalidomide.
    Fernandez de Larrea, Carlos
    Teresa Cibeira, Maria
    Navarro, Alfons
    Diaz, Tania
    Fuster, Dolors
    Tovar, Natalia
    Rosinol, Laura
    Monzo, Mariano
    Blade, Joan
    BLOOD, 2010, 116 (21) : 1647 - 1648
  • [25] Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
    Puigmarti, C. L.
    Santos, N.
    Mostacedo, S.
    Gonzalez, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab
    Lancman, Guido
    Sastow, Dahniel
    Aslanova, Minira
    Moshier, Erin
    Cho, Hearn Jay
    Jagannath, Sundar
    Madduri, Deepu
    Parekh, Samir
    Richard, Shambavi
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD, 2020, 136
  • [27] Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM).
    Barlogie, D
    Spencer, T
    Tricot, G
    Zeldis, J
    Munshi, N
    Zangari, M
    Badros, A
    Toor, A
    Shaughnessy, J
    Morris, C
    Desikan, R
    LEUKEMIA, 2001, 15 (03) : 491 - 491
  • [28] Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease.
    Desikan, R
    Munshi, N
    Zeldis, J
    Eddlemon, P
    Badros, A
    Zangari, M
    Singhal, S
    Mehta, J
    Ayers, D
    Lim, S
    Wilson, C
    Anaissie, E
    Crowley, J
    Barlogie, B
    BLOOD, 1999, 94 (10) : 603A - 603A
  • [29] Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients.
    Grosbois, B
    Bellissant, E
    Moreau, P
    Attal, M
    Zerbib, R
    BLOOD, 2001, 98 (11) : 163A - 163A
  • [30] Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM).
    Barlogie, B
    Spencer, T
    Tricot, G
    Zeldis, J
    Munshi, N
    Zangari, M
    Badros, A
    Toor, A
    Shaughnessy, J
    Morris, C
    Desikan, R
    BLOOD, 2000, 96 (11) : 514A - 514A
12345